Gilead Sciences (GILD) Cash from Investing Activities Growth (3y) (2012 - 2026)
Gilead Sciences (GILD) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -43.40% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -77.58% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -39.19% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -177.73% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 27.70% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 83.15% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -177.73% |
| Mar 31, 2026 | 60.61% |
| Dec 31, 2025 | -69.77% |
| Sep 30, 2025 | 15.71% |
| Jun 30, 2025 | -90.10% |
| Mar 31, 2025 | 27.07% |
| Dec 31, 2024 | 6.81% |
| Sep 30, 2024 | -44.77% |
| Jun 30, 2024 | 18.97% |
| Mar 31, 2024 | -2.62% |
| Dec 31, 2023 | 56.74% |
| Sep 30, 2023 | 5.46% |
| Jun 30, 2023 | 54.19% |
| Mar 31, 2023 | -33.91% |
| Dec 31, 2022 | -42.11% |
| Sep 30, 2022 | 27.11% |
| Jun 30, 2022 | 63.17% |
| Mar 31, 2022 | -63.68% |
| Dec 31, 2021 | -28.09% |
| Sep 30, 2021 | -28.37% |